What are the latency programs of Epstein-Barr virus and the associated clinical manifestations?

EBV Latency Programs and Associated Clinical Manifestations

EBV establishes three distinct latency programs (Latency I, II, and III) characterized by differential viral protein expression, with each program associated with specific disease manifestations ranging from asymptomatic infection to life-threatening malignancies.

EBV Latency Programs

The virus expresses six different EBV nuclear antigens (EBNAs), three latent membrane proteins (LMPs), and two EBV-encoded RNAs (EBERs) during latent infection, with distinct expression patterns defining each latency type 1:

Latency I (Most Restrictive)

• Viral proteins expressed: EBNA-1 and EBERs only
• Associated diseases: Burkitt lymphoma (BL)
• Clinical significance: These tumors evade immune surveillance because they express minimal viral antigens, making them resistant to EBV-specific T-cell therapies 2

Latency II (Intermediate)

• Viral proteins expressed: EBNA-1, EBERs, and LMPs (LMP1, LMP2A/B)
• Associated diseases:
  • Nasopharyngeal carcinoma (NPC)
  • Hodgkin disease (HD)
  • T-cell or NK-cell lymphomas
  • Some cases of chronic active EBV infection (CAEBV) 1

Latency III (Full Expression)

• Viral proteins expressed: All EBNAs (EBNA-1, EBNA-2, EBNA-3 family, EBNA-LP), all LMPs, and EBERs
• Associated diseases:
  • Post-transplant lymphoproliferative disorders (PTLD) in immunocompromised patients
  • Severe CAEBV
  • EBV-associated lymphoproliferative disorders 3, 1
• Immunologic importance: EBNA-2, EBNA-3 family, and LMP-1 are major targets of EBV-specific cytotoxic T lymphocytes, making these tumors potentially responsive to T-cell therapies 1

Important caveat: Recent evidence demonstrates heterogeneous expression patterns within tissues, with cells displaying mixed latency phenotypes (e.g., EBNA2+/LMP1- or EBNA2-/LMP1+) 4. This heterogeneity complicates both diagnosis and therapeutic targeting.

Clinical Manifestations by Disease State

Acute Infectious Mononucleosis (IM)

• Presents with persistent or intermittent fever, lymphadenopathy, pharyngitis
• EBV primarily infects B-lymphocytes, many showing plasma cell differentiation
• Displays variable latency patterns including Latency I, II, and III phenotypes within the same patient 4
• Self-limiting in immunocompetent hosts

Chronic Active EBV Infection (CAEBV)

Diagnostic criteria require 1:

1. Persistent or recurrent IM-like symptoms (fever, lymphadenopathy)
2. High IgG antibody titers against EBV VCA (≥1:640) and EA (≥1:160)
3. Elevated EBV DNA in peripheral blood (>10^2.5 copies/mg DNA) 1
4. Absence of other defined underlying disease at diagnosis

Clinical presentations 1:

• Persistent high fever, massive lymphadenopathy
• Hepatosplenomegaly
• Interstitial pneumonitis
• Thrombocytopenia
• Hypersensitivity to mosquito bites (characteristic in some patients)
• Hydroa vacciniforme-like skin eruptions

Critical prognostic factors 1:

• Late onset of disease
• Thrombocytopenia
• EBV infection of T cells (versus B cells)
• Higher histopathologic grade (Grade 3 neoplastic lesions)

Mortality risk: Historically 84.6% before 2000; improved to approximately one-third with modern management including rituximab and preemptive therapy 3. However, CAEBV carries significant risk of progression to T-cell or NK-cell malignant lymphomas 1.

Post-Transplant Lymphoproliferative Disorders (PTLD)

After hematopoietic stem cell transplant:

• Almost exclusively EBV-related (unlike solid organ transplant) 3
• Express Latency III program with full viral antigen expression
• Diagnosis requires 3:
  • Probable: Significant lymphadenopathy/hepatosplenomegaly with significant EBV DNA-emia, no other documented cause
  • Proven: EBV nucleic acids or proteins in tissue specimen plus symptoms from affected organ

Histopathologic classification (WHO) 3:

• Polyclonal early lesions
• Polymorphic PTLD
• Monomorphic PTLD (B-cell or T/NK-cell)
• Classical Hodgkin lymphoma-type PTLD

EBV-Associated Malignancies

Burkitt Lymphoma:

• Latency I program
• Minimal viral antigen expression
• Resistant to T-cell immunotherapy

Nasopharyngeal Carcinoma, Hodgkin Disease, T/NK-cell Lymphomas:

• Latency II program
• Express EBNA-1, EBERs, and LMPs
• Potentially responsive to immunotherapy targeting LMP antigens

Key Diagnostic Pitfalls

1. Do not diagnose CAEBV in patients with pathologically confirmed T-cell or NK-cell lymphoproliferative disorders - use the specific disease name instead 1

2. EBV DNA in blood alone is insufficient for PTLD diagnosis - requires tissue confirmation with EBER in situ hybridization (gold standard) 3

3. Perform multisite biopsies when evaluating CAEBV - spatial heterogeneity exists, with extramedullary sites often showing higher-grade disease than bone marrow 5

4. Antibody titers are not standardized between laboratories - interpret in context of local reference ranges 1

5. Mixed immunophenotypes (T/NK-cell) in CAEBV correlate with higher-grade disease (60% in Grade-3 versus 11.3% in Grade-1) and may influence treatment planning 5